Intellectual Property, Pharmaceuticals and Public Health

Intellectual Property, Pharmaceuticals and Public Health

Access to Drugs in Developing Countries

Edited by Kenneth C. Shadlen, Samira Guennif, Alenka Guzmán and N. Lalitha

This up-to-date book examines pharmaceutical development, access to medicines, and the protection of public health in the context of two fundamental changes that the global political economy has undergone since the 1970s, the globalization of trade and production and the increased harmonization of national regulations on intellectual property rights.

Chapter 8: Pharmaceutical Patent Policy in Developing Countries: Learning from the Canadian Experience

Jean-Frédéric Morin and Mélanie Bourassa Forcier

Subjects: development studies, development economics, law and development, economics and finance, development economics, health policy and economics, political economy, law - academic, intellectual property law, law and development, politics and public policy, political economy, social policy and sociology, health policy and economics


1 Jean-Frédéric Morin and Mélanie Bourassa Forcier It is often believed that Canada is in a delicate position as regards adopting a strongly different patent policy from the United States. It is true that the Canadian economy is still greatly, although decreasingly, dependent on its southern neighbor. The Canadian government intentionally strengthened these economic and industrial ties by signing a bilateral free trade agreement (FTA) with the US in 1987, followed by the North American Free Trade Agreement (NAFTA) in 1992. In 2008, 78 per cent of Canadian exports were destined for the US market and 58 per cent of foreign direct investment stock in Canada was owned by American investors (Canada 2009). Few other countries, including in Latin America, are as dependent on the US economy and therefore vulnerable to US trade pressures regarding their pharmaceutical patent policy. Nevertheless, Canada did not hesitate to depart from the US model to design a unique patent policy for pharmaceutical products. The history of the Canadian pharmaceutical patent policy, although increasingly imprinted by US influences, reveals a Canadian philosophy for justice in access to health care services. One could even argue that universal access to health services is a symbol of the Canadian identity and a source of national pride, enabling Canadians to distinguish themselves from Americans. In 2004, Tommy Douglas, a politician known as Canada’s father of Medicare, was named the Greatest Canadian of all time in a nationwide contest casting over 1.2 million votes. Few other nations,...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information